- Home
- IPA vs LEXX Comparison
IPA vs LEXX Comparison
Compare IPA & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- LEXX
- Stock Information
- Founded
- IPA 1983
- LEXX 2004
- Country
- IPA United States
- LEXX Canada
- Employees
- IPA N/A
- LEXX 7
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- LEXX Health Care
- Exchange
- IPA Nasdaq
- LEXX Nasdaq
- Market Cap
- IPA 20.6M
- LEXX 23.3M
- IPO Year
- IPA 2017
- LEXX N/A
- Fundamental
- Price
- IPA $0.45
- LEXX $1.08
- Analyst Decision
- IPA Strong Buy
- LEXX Strong Buy
- Analyst Count
- IPA 2
- LEXX 1
- Target Price
- IPA $4.00
- LEXX $7.00
- AVG Volume (30 Days)
- IPA 407.1K
- LEXX 103.5K
- Earning Date
- IPA 03-28-2025
- LEXX 04-14-2025
- Dividend Yield
- IPA N/A
- LEXX N/A
- EPS Growth
- IPA N/A
- LEXX N/A
- EPS
- IPA N/A
- LEXX N/A
- Revenue
- IPA $16,581,105.00
- LEXX $525,923.00
- Revenue This Year
- IPA $4.67
- LEXX $30.72
- Revenue Next Year
- IPA $14.15
- LEXX $31.85
- P/E Ratio
- IPA N/A
- LEXX N/A
- Revenue Growth
- IPA 1.34
- LEXX 29.95
- 52 Week Low
- IPA $0.27
- LEXX $1.11
- 52 Week High
- IPA $1.36
- LEXX $4.44
- Technical
- Relative Strength Index (RSI)
- IPA 52.32
- LEXX 36.47
- Support Level
- IPA $0.45
- LEXX $1.01
- Resistance Level
- IPA $0.48
- LEXX $1.69
- Average True Range (ATR)
- IPA 0.03
- LEXX 0.10
- MACD
- IPA 0.00
- LEXX -0.02
- Stochastic Oscillator
- IPA 55.57
- LEXX 10.29
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.